Skip to main content
. Author manuscript; available in PMC: 2018 Oct 1.
Published in final edited form as: Ann Surg Oncol. 2018 Feb 13;25(4):1000–1008. doi: 10.1245/s10434-017-6290-8

FIG. 3.

FIG. 3

a Overall survival for all patients diagnosed with PDAC in the study, separated into subsets of patients with resected tumors (n = 40, blue), locally advanced disease treated palliatively (n = 12, yellow), occult metastatic disease (n = 12, orange), or metastatic disease (n = 25, green). Patients with occult metastatic disease had survival similar to patients with radiologically visible metastatic disease, and significantly different from patients with early-stage or locally advanced disease. b Overall survival for all patients stratified by CTC count (n = 100). c Time to recurrence for patients after surgical resection stratified by CTC count (n = 40). CTC circulating tumor cell, PDAC pancreatic ductal adenocarcinoma